Microgynon ED 50: Discontinuation

Microgynon ED 50 is being discontinued by the supplier. We anticipate stock to run out in May 2021.

About Microgynon ED 50

Microgynon ED 50 is a higher dose hormonal contraceptive. It is usually prescribed to people taking an enzyme inducing antiepileptic medicine to counteract the change in hepatic metabolism. Its active ingredients are ethinyloestradiol 50 mcg and levonorgestrel 150 mcg. 

We estimate there are about 1,500 people taking Microgynon ED 50.

Prescribers: What you need to know

Members of the Reproductive and Sexual Health Subcommittee have advised us that there are listed alternative contraceptives that are unaffected by enzyme-inducers. BPAC offers advice on prescribing antiepileptics and contraceptives.

Read Balancing the benefits and risks of prescribing antiepileptic medicines on BPAC's website(external link)

Read about antiepileptics on the NZ Formulary(external link)

Check the Schedule for funded contraceptives(external link)

We ask that prescribers reach out to their patients taking Microgynon ED 50 early to transition them to a new contraceptive. 

We know that changing people's medication can be inconvenient. We appreciate your time in helping people make these changes. 

People who take Microgynon ED 50: What you need to do

You will need to talk to your prescriber about which funded contraceptive is best for you and your clinical circumstances. There are a number of funded contraceptive options that might be suitable. In recent years, PHARMAC has funded a range of long-acting reversible contraceptives which may be better alternatives to Microgynon ED 50.

Pharmacists: What you need to know

Product details

  • Brand name: Microgynon ED 50
  • Formulation: Tab 50 mcg with levonorgestrel 125 mcg and 7 inert tab 
  • Pharmacode: 202827

Key dates

  • May 2021: supplies of Microgynon ED 50 are depleted
  • 1 January 2022: Microgynon ED 50 delisted from the Schedule

Who to contact

If you take Microgynon ED 50, you will need to talk to your prescriber about alternatives. PHARMAC cannot give individual clinical advice.

If you have questions about funding for alternative contraceptives, email enquiry@pharmac.govt.nz